C. Lukacs

发表

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

L. Vassilev, B. Vu, B. Graves, 2004, Science.

Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.

A. Polonskaia, C. Lukacs, Hongmao Sun, 2013, Bioorganic & medicinal chemistry letters.

3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors.

U. Kammlott, C. Lukacs, Yi Chen, 2003, Bioorganic & medicinal chemistry letters.

Structural change in alpha-chymotrypsin induced by complexation with alpha 1-antichymotrypsin as seen by enhanced sensitivity to proteolysis.

W. T. Moore, C. Lukacs, J. Lambris, 1996, Biochemistry.

Structural Change in α-Chymotrypsin Induced by Complexation with α1-Antichymotrypsin As Seen by Enhanced Sensitivity to Proteolysis†

John D Lambris, W. T. Moore, C. Lukacs, 1996 .

mRNA Therapy Improves Metabolic and Behavioral Abnormalities in a Murine Model of Citrin Deficiency.

C. Lukacs, L. Guey, P. Giangrande, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.

C. Lukacs, C. Janson, C. Belunis, 2011, Bioorganic & medicinal chemistry letters.

Systematic literature review and meta-analysis on the epidemiology of methylmalonic acidemia (MMA) with a focus on MMA caused by methylmalonyl-CoA mutase (mut) deficiency

C. Lukacs, L. Guey, Z. Vokó, 2019, Orphanet Journal of Rare Diseases.

Systematic literature review and meta-analysis on the epidemiology of propionic acidemia

C. Lukacs, L. Guey, Z. Vokó, 2019, Orphanet Journal of Rare Diseases.

Discovery of a Novel Site Regulating Glucokinase Activity following Characterization of a New Mutation Causing Hyperinsulinemic Hypoglycemia in Humans*

S. Ellard, C. Lukacs, A. Gloyn, 2011, The Journal of Biological Chemistry.

Pyrazolobenzodiazepines: part I. Synthesis and SAR of a potent class of kinase inhibitors.

C. Lukacs, P. Rossman, P. Wovkulich, 2010, Bioorganic & medicinal chemistry letters.

BglII and MunI: what a difference a base makes.

C. Lukacs, A. Aggarwal, 2001, Current opinion in structural biology.

Synthesis of potential inhibitors of hemagglutination by influenza virus: chemoenzymic preparation of N-5 analogs of N-acetylneuraminic acid.

G. Whitesides, C. Lukacs, A. Spaltenstein, 1993 .

Discovery of a novel series of 4-quinolone JNK inhibitors.

C. Lukacs, A. Kuglstatter, Brian R. Wong, 2012, Bioorganic & medicinal chemistry letters.

Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia

C. Lukacs, L. Guey, D. An, 2019, EBioMedicine.

Alzheimer’s Peptide Aβ1–42 Binds to Two β-Sheets of α1-Antichymotrypsin and Transforms It from Inhibitor to Substrate*

C. Lukacs, H. Rubin, S. Janciauskiene, 1998, The Journal of Biological Chemistry.

Synthesis of Potential Inhibitors of Hemagglutination by Influenza Virus: Chemoenzymic Preparation of N‐5 Analogues of N‐Acetylneuraminic Acid.

G. Whitesides, C. Lukacs, A. Spaltenstein, 1993 .

Understanding the immutability of restriction enzymes: crystal structure of BglII and its DNA substrate at 1.5 Å resolution

C. Lukacs, A. Aggarwal, R. Kucera, 2000, Nature Structural Biology.

Is the binding of β‐amyloid protein to antichymotrypsin in Alzheimer plaques mediated by a β‐strand insertion?

C. Lukacs, D. Christianson, 1996 .

Crystal Structure of Human Liver Glucokinase Bound to a Small Molecule Allosteric Activator

U. Kammlott, C. Lukacs, J. Grippo, 2004 .

Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

C. Lukacs, M. Alegre, L. Guey, 2018, Nature Medicine.

Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domain.

Robert T. Taylor, A. Polonskaia, M. Weisel, 2013, Journal of medicinal chemistry.

Identification of an Adamantyl Azaquinolone JNK Selective Inhibitor.

C. Lukacs, C. Janson, A. Railkar, 2012, ACS medicinal chemistry letters.

Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain.

A. Polonskaia, M. Weisel, C. Lukacs, 2013, Journal of medicinal chemistry.

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia

C. Lukacs, L. Guey, M. Theisen, 2017, Cell reports.

Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.

Johannes C. Hermann, C. Lukacs, A. Kuglstatter, 2014, Journal of medicinal chemistry.

Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.

C. Lukacs, L. Guey, K. Burke, 2019, American journal of human genetics.

High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein

C. Lukacs, C. Espiritu, A. Lam, 2015, Proceedings of the National Academy of Sciences.

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Christof Fellmann, Scott Lowe, Neal Rosen, 2014, Cancer cell.

Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.

Nader Fotouhi, Sung-Sau So, S. So, 2006, Journal of medicinal chemistry.

Optimization of ether and aniline based inhibitors of lactate dehydrogenase.

D. Urban, A. Jadhav, M. Hall, 2021, Bioorganic & medicinal chemistry letters.

Fragment-Based Drug Design of Novel Pyranopyridones as Cell Active and Orally Bioavailable Tankyrase Inhibitors.

Johannes C. Hermann, D. Carvajal, C. Lukacs, 2015, ACS medicinal chemistry letters.

Alzheimer's peptide Abeta1-42 binds to two beta-sheets of alpha1-antichymotrypsin and transforms it from inhibitor to substrate.

C. Lukacs, H. Rubin, S. Janciauskiene, 1998, The Journal of biological chemistry.

Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4−/− mouse model of PFIC3

P. An, C. Lukacs, P. Giangrande, 2020, Journal of hepatology.

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy

Johannes C. Hermann, C. Lukacs, Seng-Lai Tan, 2013, Arthritis Research & Therapy.

Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia

C. Lukacs, L. Guey, C. Mihai, 2020, Nature Communications.

Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH).

D. Urban, A. Jadhav, C. Dang, 2017, Journal of medicinal chemistry.

Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor.

Binh Vu, David C Fry, B. Vu, 2013, ACS medicinal chemistry letters.

Development of amino-pyrimidine inhibitors of c-Jun N-terminal kinase (JNK): kinase profiling guided optimization of a 1,2,3-benzotriazole lead.

Johannes C. Hermann, C. Lukacs, A. Kuglstatter, 2013, Bioorganic & medicinal chemistry letters.

Two of A Kind: BamHI and BglII

C. Lukacs, H. Viadiu, A. Aggarwal, 2004 .

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Thelma Thompson, David Fry, Kuo-Sen Huang, 2012, Proceedings of the National Academy of Sciences.

Systemic messenger RNA as an etiological treatment for acute intermittent porphyria

C. Lukacs, M. Alegre, L. Guey, 2018, Nature Medicine.

Structures of aspartate aminotransferases from Trypanosoma brucei, Leishmania major and Giardia lamblia.

P. Myler, C. Lukacs, W. V. Van Voorhis, 2015, Acta crystallographica. Section F, Structural biology communications.

The structure of XIAP BIR2: understanding the selectivity of the BIR domains

C. Lukacs, A. Kuglstatter, C. Janson, 2013, Acta crystallographica. Section D, Biological crystallography.

Arginine substitutions in the hinge region of antichymotrypsin affect serpin β-sheet rearrangement

C. Lukacs, B. Cooperman, D. Christianson, 1996, Nature Structural Biology.

Germinal‐center kinase‐like kinase co‐crystal structure reveals a swapped activation loop and C‐terminal extension

C. Lukacs, L. Silvian, J. Lyssikatos, 2017, Protein science : a publication of the Protein Society.

Structure of free BglII reveals an unprecedented scissor-like motion for opening an endonuclease

C. Lukacs, A. Aggarwal, R. Kucera, 2001, Nature Structural Biology.

The crystal structure of human muscle glycogen phosphorylase a with bound glucose and AMP: An intermediate conformation with T‐state and R‐state features

Chao-Min Liu, C. Lukacs, N. Oikonomakos, 2006, Proteins.

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

S. Lowe, C. Lukacs, N. Rosen, 2014, Cancer cell.